Pharmacokinetics of rimantadine hydrochloride in patients with chronic liver disease.
Six patients with chronic liver disease and six sex-, age (+/- 5 years)-, and weight (+/- 5 kg)-matched healthy control subjects received a single dose of two 100 mg tablets rimantadine HCl. Eight additional patients with chronic liver disease who were not matched to healthy subjects received a single dose of two 100 mg tablets of rimantadine HCl. Blood and urine samples were collected and rimantadine concentrations were determined by a GCMS method. The values for maximum plasma concentration, AUC, elimination half-life, and renal clearance were not significantly different between patients and control subjects, independent of the statistical analyses (parametric and nonparametric) used. The mean apparent elimination half-life, volume of distribution, and total clearance in the matched patients with liver disease were 32 hours, 24 L/kg, and 676 ml/min, respectively. Renal clearance and the amount excreted in the urine unchanged were 63 ml/min and 10%, respectively. In conclusion, rimantadine pharmacokinetics were not appreciably altered in patients with less severe chronic liver disease.
Wills
R J
RJ
Hoffmann-La Roche Inc., Nutley, NJ 07110.
Belshe
R
R
Tomlinsin
D
D
De Grazia
F
F
Lin
A
A
Wells
S
S
Milazzo
J
J
Berry
C
C
D000218:Adamantane / Q000031:analogs & derivatives*; D000328:Adult; D000368:Aged; D002908:Chronic Disease; D005260:Female; D006207:Half-Life; D006801:Humans; D008107:Liver Diseases / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D012299:Rimantadine / Q000097:blood / Q000493:pharmacokinetics* / Q000652:urine
D012299:Rimantadine; D000218:Adamantane